AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9987143 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal A + C control vaccine
Number of subjects: 83
Study 8657431 — intervention group
Group type: EXPERIMENTAL
Intervention: +tramadol
Number of subjects: 98
Study 8657431 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol racemate
Number of subjects: 98
Study 8657431 — intervention group
Group type: EXPERIMENTAL
Intervention: -tramadol
Number of subjects: 98
Study 1692602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal interferon
Number of subjects: 127
Study 1692602 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 127
Study 487092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle displacement with subject instructed to relax
Number of subjects: 18
Study 487092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle displacement with subject opposing sudden displacement
Number of subjects: 18
Study 487092 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulus response latency
Number of subjects: 18
Study 487092 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque response to ankle displacement
Number of subjects: 18
Study 487092 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of displacement velocity
Number of subjects: 18
Study 30924903 — intervention group
Group type: EXPERIMENTAL
Intervention: Indications-based computerized provider order entry prototype
Number of subjects: 32
Study 30924903 — intervention group
Group type: COMPARATOR
Intervention: Vendor 1's electronic prescribing system
Number of subjects: 32
Study 30924903 — intervention group
Group type: COMPARATOR
Intervention: Vendor 2's electronic prescribing system
Number of subjects: 32
Study 29030343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet with 15-min postmeal walks (LC + Ex)
Number of subjects: 11
Study 29030343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LC)
Number of subjects: 11
Study 29030343 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet (CON)
Number of subjects: 11
Study 26856491 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education Through Simulation‐Diabetes (PETS‐D)
Number of subjects: 0
Study 26856491 — intervention group
Group type: COMPARATOR
Intervention: Comparison data results
Number of subjects: 0
Study 23834667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bibliotherapy (4-week program)
Number of subjects: 0
Study 23834667 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 0
Study 23107250 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-in (OI) technique
Number of subjects: 39
Study 23107250 — intervention group
Group type: COMPARATOR
Intervention: Transportal (TP) technique
Number of subjects: 39
Study 19535229 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual orally disintegrating olanzapine (ODO)
Number of subjects: 0
Study 19535229 — intervention group
Group type: COMPARATOR
Intervention: Standard olanzapine tablets (SOT)
Number of subjects: 0
Study 17280773 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.1, 0.2, or 0.4 mg)
Number of subjects: 127
Study 17280773 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 127
Study 17280773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 15088136 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Z)
Number of subjects: 184
Study 15088136 — intervention group
Group type: COMPARATOR
Intervention: Home infusions
Number of subjects: 184
Study 11427834 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol PCS (0.3 mg/kg bolus, zero lockout)
Number of subjects: 88
Study 11427834 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (0.05 mg/kg bolus, 1 mg increments as required)
Number of subjects: 88
Study 9740484 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiograms (quantitative coronary angiography)
Number of subjects: 419
Study 9740484 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline number of all stenoses
Number of subjects: 419
Study 9740484 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fatal myocardial infarcts and revascularization procedures
Number of subjects: 419
Study 9740484 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade stenoses in the left anterior descending artery
Number of subjects: 419
Study 9740484 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline left ventricular ejection fraction
Number of subjects: 419
Study 7873476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amiodarone
Number of subjects: 0
Study 7873476 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3145014 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cephradine
Number of subjects: 400
Study 3145014 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g mezlocillin
Number of subjects: 400
Study 3145014 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 400
Study 3145014 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g cephradine
Number of subjects: 400
Study 29920432 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential child abuse occurring in their neighborhood
Number of subjects: 946
Study 29920432 — intervention group
Group type: COMPARATOR
Intervention: Potential child abuse in an unfamiliar neighborhood
Number of subjects: 946
Study 29920432 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher collective efficacy scores
Number of subjects: 946
Study 29920432 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences
Number of subjects: 946
Study 26935243 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression use during exercise intervention
Number of subjects: 41
Study 25363124 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPA-based intervention with family support
Number of subjects: 96
Study 25363124 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 22613524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-axis rotational coronary angiography (DARCA)
Number of subjects: 200
Study 22613524 — intervention group
Group type: COMPARATOR
Intervention: Standard coronary angiography (SA)
Number of subjects: 200
Study 19362286 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled transanal rectal resection alone or associated with transobturator tape, vaginal repair of the enterocele, or vaginal hysterectomy
Number of subjects: 142
Study 19362286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rectal and urogynecologic surgery with vaginal hysterectomy
Number of subjects: 142
Study 17720629 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach incorporating external and subjective information
Number of subjects: 0
Study 17720629 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian methodology
Number of subjects: 0
Study 17720629 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal synthesis of external evidence
Number of subjects: 0
Study 16001909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring stretching
Number of subjects: 1338
Study 11909508 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus behavior management group
Number of subjects: 27
Study 11909508 — intervention group
Group type: COMPARATOR
Intervention: Education only group
Number of subjects: 27
Study 11909508 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 10322619 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality traits and cognitive styles (hopelessness, neuroticism, introversion, low self-esteem, impulsiveness, external locus of control)
Number of subjects: 0
Study 10322619 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals not making suicide attempts)
Number of subjects: 0
Study 8701892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus recombinant urokinase (rUK) administered as three bolus infusions of 1 million U over a 24-hour period
Number of subjects: 17
Study 8701892 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 17
Study 8701892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus recombinant urokinase (rUK)
Number of subjects: 17
Study 8701892 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 17
Study 8370856 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 3
Study 8370856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 3
Study 8370856 — intervention group
Group type: COMPARATOR
Intervention: Nondirective (ND) therapy
Number of subjects: 3
Study 2873756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 153
Study 2873756 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 153
Study 29432644 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA (5-aminolaevulinic acid gel)
Number of subjects: 281
Study 29432644 — intervention group
Group type: COMPARATOR
Intervention: MAL (methyl aminolaevulinate cream)
Number of subjects: 281
Study 27769226 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 237
Study 27769226 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237
Study 27769226 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline diagnosis of psychosis
Number of subjects: 237
Study 26089301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification
Number of subjects: 307
Study 26089301 — intervention group
Group type: COMPARATOR
Intervention: Slow freezing
Number of subjects: 307
Study 23925143 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant surfactant
Number of subjects: 0
Study 23925143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21569169 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention combining a feedback curriculum with a card system
Number of subjects: 15
Study 21569169 — intervention group
Group type: COMPARATOR
Intervention: Control group (current feedback method)
Number of subjects: 15
Study 19468050 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 16
Study 19468050 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen plus medroxyprogesterone acetate
Number of subjects: 16
Study 19468050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (general)
Number of subjects: 16
Study 16306466 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 6602
Study 16306466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 6602
Study 16306466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study 12826700 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant follicle-stimulating hormone (recFSH) 2 x 225 IU per week + hCG
Number of subjects: 30
Study 12826700 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant follicle-stimulating hormone (recFSH) 3 x 150 IU per week + hCG
Number of subjects: 30
Study 12826700 — intervention group
Group type: COMPARATOR
Intervention: hCG alone (pre-treatment)
Number of subjects: 30
Study 12826700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined gonadotropin treatment
Number of subjects: 30
Study 12826700 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with a history of maldescended testes
Number of subjects: 30
Study 10709886 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children
Number of subjects: 18
Study 10709886 — intervention group
Group type: COMPARATOR
Intervention: HIV-seroreverter children
Number of subjects: 18
Study 7793186 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain 0.15% bupivacaine (150 mg.100 ml‐1)
Number of subjects: 60
Study 7793186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline (1.5 micrograms ml‐1)
Number of subjects: 60
Study 7793186 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 1828183 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH analogue Zoladex (administered subcutaneously every 28 days)
Number of subjects: 358
Study 1828183 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 358
Study 1828183 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH analogue Zoladex
Number of subjects: 358
Study 6758745 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1950 mg/day orally)
Number of subjects: 0
Study 6758745 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg/day orally)
Number of subjects: 0
Study 30166425 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatically titrated O2 flows (FreeO2)
Number of subjects: 12
Study 30166425 — intervention group
Group type: COMPARATOR
Intervention: Constant O2 flow
Number of subjects: 12
Study 28368940 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 28368940 — intervention group
Group type: EXPERIMENTAL
Intervention: New formula for estimating blood loss
Number of subjects: 0
Study 28368940 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas of Gross, Bourke and Smith, and Camarasa
Number of subjects: 0
Study 28368940 — intervention group
Group type: COMPARATOR
Intervention: Camarasa's formula
Number of subjects: 0
Study 25765144 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Monitoring (OM)
Number of subjects: 32
Study 25765144 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Attention (FA)
Number of subjects: 32
Study 25765144 — intervention group
Group type: COMPARATOR
Intervention: General Relaxation (Control)
Number of subjects: 32
Study 23848826 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg TZP-102 once daily for 12 weeks
Number of subjects: 201
Study 23848826 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg TZP-102 once daily for 12 weeks
Number of subjects: 201
Study 23848826 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 201
Study 23848826 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg TZP-102 three-times-daily for 12 weeks (Study TZP-102-CL-G004)
Number of subjects: 201
Study 23848826 — intervention group
Group type: COMPARATOR
Intervention: Placebo three-times-daily for 12 weeks (Study TZP-102-CL-G004)
Number of subjects: 201
Study 22006729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,470 nm diode laser (4-5 W power)
Number of subjects: 20
Study 22006729 — intervention group
Group type: COMPARATOR
Intervention: 940 nm diode laser (12 W power)
Number of subjects: 20
Study 22006729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,470 nm diode laser
Number of subjects: 20
Study 22006729 — intervention group
Group type: COMPARATOR
Intervention: 940 nm diode laser
Number of subjects: 20
Study 19833272 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.25%
Number of subjects: 66
Study 19833272 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 0.5%
Number of subjects: 66
Study 19833272 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Number of subjects: 66
Study 16710890 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Group B)
Number of subjects: 48
Study 16710890 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (Group C)
Number of subjects: 48
Study 16710890 — intervention group
Group type: COMPARATOR
Intervention: Standard FBS with airway topic anesthesia (Group A)
Number of subjects: 48
Study 14722679 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D‐MSPECT
Number of subjects: 54
Study 14722679 — intervention group
Group type: EXPERIMENTAL
Intervention: QGS
Number of subjects: 54
Study 11385055 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily)
Number of subjects: 28
Study 11385055 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily)
Number of subjects: 28
Study 11385055 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 28
Study 11385055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9089426 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (7.8 mg/24 hr)
Number of subjects: 15
Study 9089426 — intervention group
Group type: COMPARATOR
Intervention: Baseline (drug-free) response to tyramine
Number of subjects: 15
Study 7824763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam 30 mg/day
Number of subjects: 40
Study 7824763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam 60 mg/day
Number of subjects: 40
Study 7824763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam 90 mg/day
Number of subjects: 40
Study 7824763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3278631 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 60
Study 3278631 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60
Study 3278631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31634450 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS
Number of subjects: 14
Study 31634450 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 14
Study 28589238 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (550 mg three times daily for 2 weeks, followed by two 2-week repeat courses)
Number of subjects: 73
Study 28589238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 26608978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Support Team (NST)
Number of subjects: 50
Study 26608978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 23142439 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg zoledronic acid intravenous infusion
Number of subjects: 51
Study 23142439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 21251030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics, probiotics, and synbiotics
Number of subjects: 9
Study 21251030 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 9
Study 21251030 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 9
Study 21251030 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 9
Study 18645274 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release doxazosin 4 mg, once a day in the morning, for 2 years
Number of subjects: 65
Study 18645274 — intervention group
Group type: COMPARATOR
Intervention: Bladder catheterization without medication
Number of subjects: 65
Study 17142523 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (measured in estimated-metabolic-equivalent hours)
Number of subjects: 663
Study 17142523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense physical activity (measured in hours)
Number of subjects: 663
Study 12548324 — intervention group
Group type: EXPERIMENTAL
Intervention: A single course of corticosteroids (two 12 mg doses of betamethasone given IM 24 hours apart, or four 6 mg doses of dexamethasone given IM 12 hours apart)
Number of subjects: 0
Study 12548324 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat courses of corticosteroids (not routinely recommended)
Number of subjects: 0
Study 11049894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) administered in two bolus doses of 10 mg/kg each, plus a continuous infusion of 1.0 mg/kg/h for 10 hours after the first bolus.
Number of subjects: 40
Study 11049894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) administered as described above.
Number of subjects: 40
Study 11049894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid).
Number of subjects: 40
Study 8694209 — intervention group
Group type: COMPARATOR
Intervention: Standard arrangement of the T piece
Number of subjects: 10
Study 8694209 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer expiratory limb
Number of subjects: 10
Study 8694209 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered T piece arrangement
Number of subjects: 10
Study 8694209 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased length of the inspiratory limb
Number of subjects: 10
Study 1558239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyonics Dynamic Cruciate Tester
Number of subjects: 100
Study 1558239 — intervention group
Group type: EXPERIMENTAL
Intervention: Acufex Knee Signature System
Number of subjects: 100
Study 1558239 — intervention group
Group type: EXPERIMENTAL
Intervention: KT‐1000
Number of subjects: 100
Study 1558239 — intervention group
Group type: EXPERIMENTAL
Intervention: Stryker Knee Laxity Tester
Number of subjects: 100
Study 1558239 — intervention group
Group type: EXPERIMENTAL
Intervention: Genucom Knee Analysis System
Number of subjects: 100
Study 1558239 — intervention group
Group type: EXPERIMENTAL
Intervention: KSS
Number of subjects: 100
Study 3994882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0
Study 3994882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 0
Study 3994882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of pancuronium and tubocurarine
Number of subjects: 0
Study 30111216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine (Group A)
Number of subjects: 120
Study 30111216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% ropivacaine (Group B)
Number of subjects: 120
Study 30111216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (Group C)
Number of subjects: 120
Study 30111216 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (Group D)
Number of subjects: 120
Study 30111216 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Groups B and C
Number of subjects: 120
Study 26666519 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg carnitine supplements
Number of subjects: 60
Study 26666519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24671945 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control (TGC)
Number of subjects: 980
Study 24671945 — intervention group
Group type: COMPARATOR
Intervention: Standard care (STD)
Number of subjects: 980